FDA approves Johnson & Johnson’s nasal spray for depression

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants.
FDA approves standalone nasal spray to treat depression
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Nasal spray approved to help treat depression
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
Seniors who are children of divorce face greater stroke risk, study finds
Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.
Report: Hawai‘i Prison Guards Face ‘Unsustainable’ Working Conditions
Staff vacancies require corrections officers to work at least 16- or 24-hour shifts, and the mandatory overtime takes a toll.
Pharm Exec10h
The Ups and Downs of AI for Pharma Investors
Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.
Pregnancy raises risks to mental health in MS patients, study says
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.
Scientists discover type of exercise that's a 'natural Ozempic' - it cuts appetite
Scientists at the University of Virginia have uncovered how different exercise intensifies the impact of the hunger hormone ghrelin in the body.
BioSpace1d
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Chattanooga Times Free Press2d
TennCare’s maternal death rates are 3 times those of private insurance
Tennessee has long had one of the highest maternal death rates in the nation, but newly released data shows the risks of ...